<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35288456</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>04</Month>
        <Day>25</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>03</Day>
      </DateRevised>
      <Article PubModel="Electronic-Print">
        <Journal>
          <ISSN IssnType="Electronic">2575-1077</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>5</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Life science alliance</Title>
          <ISOAbbreviation>Life Sci Alliance</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Single serine on TSC2 exerts biased control over mTORC1 activation mediated by ERK1/2 but not Akt.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">e202101169</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.26508/lsa.202101169</ELocationID>
        <Abstract>
          <AbstractText>Tuberous sclerosis complex-2 (TSC2) negatively regulates mammalian target of rapamycin complex 1 (mTORC1), and its activity is reduced by protein kinase B (Akt) and extracellular response kinase (ERK1/2) phosphorylation to activate mTORC1. Serine 1364 (human) on TSC2 bidirectionally modifies mTORC1 activation by pathological growth factors or hemodynamic stress but has no impact on resting activity. We now show this modification biases to ERK1/2 but not Akt-dependent TSC2-mTORC1 activation. Endothelin-1-stimulated mTORC1 requires ERK1/2 activation and is bidirectionally modified by phospho-mimetic (S1364E) or phospho-silenced (S1364A) mutations. However, mTORC1 activation by Akt-dependent stimuli (insulin or PDGF) is unaltered by S1364 modification. Thrombin stimulates both pathways, yet only the ERK1/2 component is modulated by S1364. S1364 also has negligible impact on mTORC1 regulation by energy or nutrient status. In vivo, diet-induced obesity, diabetes, and fatty liver couple to Akt activation and are also unaltered by TSC2 S1364 mutations. This contrasts to prior reports showing a marked impact of both on pathological pressure-stress. Thus, S1364 provides ERK1/2-selective mTORC1 control and a genetic means to modify pathological versus physiological mTOR stimuli.</AbstractText>
          <CopyrightInformation>© 2022 Dunkerly-Eyring et al.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Dunkerly-Eyring</LastName>
            <ForeName>Brittany L</ForeName>
            <Initials>BL</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pan</LastName>
            <ForeName>Shi</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pinilla-Vera</LastName>
            <ForeName>Miguel</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>McKoy</LastName>
            <ForeName>Desirae</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mishra</LastName>
            <ForeName>Sumita</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Grajeda Martinez</LastName>
            <ForeName>Maria I</ForeName>
            <Initials>MI</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Oeing</LastName>
            <ForeName>Christian U</ForeName>
            <Initials>CU</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ranek</LastName>
            <ForeName>Mark J</ForeName>
            <Initials>MJ</Initials>
            <AffiliationInfo>
              <Affiliation>Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kass</LastName>
            <ForeName>David A</ForeName>
            <Initials>DA</Initials>
            <Identifier Source="ORCID">0000-0003-1596-2299</Identifier>
            <AffiliationInfo>
              <Affiliation>Division of Cardiology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD, USA dkass@jhmi.edu.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Molecular Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>F31 HL143905</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>R35 HL135827</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
          <Grant>
            <GrantID>T32 HL007227</GrantID>
            <Acronym>HL</Acronym>
            <Agency>NHLBI NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>03</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Life Sci Alliance</MedlineTA>
        <NlmUniqueID>101728869</NlmUniqueID>
        <ISSNLinking>2575-1077</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D000077005">Tuberous Sclerosis Complex 2 Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D025521">Tumor Suppressor Proteins</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>452VLY9402</RegistryNumber>
          <NameOfSubstance UI="D012694">Serine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D000076222">Mechanistic Target of Rapamycin Complex 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D051057">Proto-Oncogene Proteins c-akt</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <SupplMeshList>
        <SupplMeshName Type="Disease" UI="C566021">Tuberous Sclerosis 2</SupplMeshName>
      </SupplMeshList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020935" MajorTopicYN="Y">MAP Kinase Signaling System</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000076222" MajorTopicYN="Y">Mechanistic Target of Rapamycin Complex 1</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051057" MajorTopicYN="N">Proto-Oncogene Proteins c-akt</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D012694" MajorTopicYN="N">Serine</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000077005" MajorTopicYN="Y">Tuberous Sclerosis Complex 2 Protein</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D025521" MajorTopicYN="N">Tumor Suppressor Proteins</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>DA Kass, BL Dunkerly-Eyring, and MJ Ranek are co-inventors on a PCT patent regarding the use of TSC2 S1364/65 (human) mutations for immunological therapeutics.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>2</Month>
          <Day>25</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>15</Day>
          <Hour>5</Hour>
          <Minute>43</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>26</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35288456</ArticleId>
        <ArticleId IdType="pmc">PMC8921838</ArticleId>
        <ArticleId IdType="doi">10.26508/lsa.202101169</ArticleId>
        <ArticleId IdType="pii">5/6/e202101169</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Anfossi G, Russo I, Doronzo G, Trovati M (2009) Contribution of insulin resistance to vascular dysfunction. Arch Physiol Biochem
115: 199–217. 10.1080/13813450903136791</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/13813450903136791</ArticleId>
            <ArticleId IdType="pubmed">19686034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ballif BA, Roux PP, Gerber SA, MacKeigan JP, Blenis J, Gygi SP (2005) Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its targets, the tuberous sclerosis tumor suppressors. Proc Natl Acad Sci U S A
102: 667–672. 10.1073/pnas.0409143102</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.0409143102</ArticleId>
            <ArticleId IdType="pmc">PMC545566</ArticleId>
            <ArticleId IdType="pubmed">15647351</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bar-Tana J (2020) Type 2 diabetes - unmet need, unresolved pathogenesis, mTORC1-centric paradigm. Rev Endocr Metab Disord
21: 613–629. 10.1007/s11154-020-09545-w</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11154-020-09545-w</ArticleId>
            <ArticleId IdType="pmc">PMC7560924</ArticleId>
            <ArticleId IdType="pubmed">32128655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bueno OF, De Windt LJ, Tymitz KM, Witt SA, Kimball TR, Klevitsky R, Hewett TE, Jones SP, Lefer DJ, Peng CF, et al.  (2000) The MEK1-ERK1/2 signaling pathway promotes compensated cardiac hypertrophy in transgenic mice. EMBO J
19: 6341–6350. 10.1093/emboj/19.23.6341</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/emboj/19.23.6341</ArticleId>
            <ArticleId IdType="pmc">PMC305855</ArticleId>
            <ArticleId IdType="pubmed">11101507</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Carroll B, Maetzel D, Maddocks OD, Otten G, Ratcliff M, Smith GR, Dunlop EA, Passos JF, Davies OR, Jaenisch R, et al.  (2016) Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity. Elife
5: e11058. 10.7554/eLife.11058</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.7554/eLife.11058</ArticleId>
            <ArticleId IdType="pmc">PMC4764560</ArticleId>
            <ArticleId IdType="pubmed">26742086</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dann SG, Selvaraj A, Thomas G (2007) mTOR Complex1-S6K1 signaling: At the crossroads of obesity, diabetes and cancer. Trends Mol Med
13: 252–259. 10.1016/j.molmed.2007.04.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molmed.2007.04.002</ArticleId>
            <ArticleId IdType="pubmed">17452018</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Davenport AP, Hyndman KA, Dhaun N, Southan C, Kohan DE, Pollock JS, Pollock DM, Webb DJ, Maguire JJ (2016) Endothelin. Pharmacol Rev
68: 357–418. 10.1124/pr.115.011833</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1124/pr.115.011833</ArticleId>
            <ArticleId IdType="pmc">PMC4815360</ArticleId>
            <ArticleId IdType="pubmed">26956245</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demetriades C, Doumpas N, Teleman AA (2014) Regulation of TORC1 in response to amino acid starvation via lysosomal recruitment of TSC2. Cell
156: 786–799. 10.1016/j.cell.2014.01.024</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2014.01.024</ArticleId>
            <ArticleId IdType="pmc">PMC4346203</ArticleId>
            <ArticleId IdType="pubmed">24529380</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Demetriades C, Plescher M, Teleman AA (2016) Lysosomal recruitment of TSC2 is a universal response to cellular stress. Nat Commun
7: 10662. 10.1038/ncomms10662</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncomms10662</ArticleId>
            <ArticleId IdType="pmc">PMC4754342</ArticleId>
            <ArticleId IdType="pubmed">26868506</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dibble CC, Cantley LC (2015) Regulation of mTORC1 by PI3K signaling. Trends Cell Biol
25: 545–555. 10.1016/j.tcb.2015.06.002</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tcb.2015.06.002</ArticleId>
            <ArticleId IdType="pmc">PMC4734635</ArticleId>
            <ArticleId IdType="pubmed">26159692</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fitzian K, Bruckner A, Brohee L, Zech R, Antoni C, Kiontke S, Gasper R, Linard Matos AL, Beel S, Wilhelm S, et al.  (2021) TSC1 binding to lysosomal PIPs is required for TSC complex translocation and mTORC1 regulation. Mol Cell
81: 2705–2721.e8. 10.1016/j.molcel.2021.04.019</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.molcel.2021.04.019</ArticleId>
            <ArticleId IdType="pubmed">33974911</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Han J, Wang Y (2018) mTORC1 signaling in hepatic lipid metabolism. Protein Cell
9: 145–151. 10.1007/s13238-017-0409-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13238-017-0409-3</ArticleId>
            <ArticleId IdType="pmc">PMC5818363</ArticleId>
            <ArticleId IdType="pubmed">28434145</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang J, Manning BD (2008) The TSC1-TSC2 complex: A molecular switchboard controlling cell growth. Biochem J
412: 179–190. 10.1042/BJ20080281</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1042/BJ20080281</ArticleId>
            <ArticleId IdType="pmc">PMC2735030</ArticleId>
            <ArticleId IdType="pubmed">18466115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Li Y, Zhu T, Wu J, Guan KL (2002) TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol
4: 648–657. 10.1038/ncb839</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb839</ArticleId>
            <ArticleId IdType="pubmed">12172553</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Ouyang H, Zhu T, Lindvall C, Wang Y, Zhang X, Yang Q, Bennett C, Harada Y, Stankunas K, et al.  (2006) TSC2 integrates Wnt and energy signals via a coordinated phosphorylation by AMPK and GSK3 to regulate cell growth. Cell
126: 955–968. 10.1016/j.cell.2006.06.055</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2006.06.055</ArticleId>
            <ArticleId IdType="pubmed">16959574</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Inoki K, Zhu T, Guan KL (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell
115: 577–590. 10.1016/s0092-8674(03)00929-2</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0092-8674(03)00929-2</ArticleId>
            <ArticleId IdType="pubmed">14651849</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kapakos G, Bouallegue A, Daou GB, Srivastava AK (2010) Modulatory role of nitric oxide/cGMP system in endothelin-1-induced signaling responses in vascular smooth muscle cells. Curr Cardiol Rev
6: 247–254. 10.2174/157340310793566055</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2174/157340310793566055</ArticleId>
            <ArticleId IdType="pmc">PMC3083805</ArticleId>
            <ArticleId IdType="pubmed">22043200</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khamzina L, Veilleux A, Bergeron S, Marette A (2005) Increased activation of the mammalian target of rapamycin pathway in liver and skeletal muscle of obese rats: Possible involvement in obesity-linked insulin resistance. Endocrinology
146: 1473–1481. 10.1210/en.2004-0921</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/en.2004-0921</ArticleId>
            <ArticleId IdType="pubmed">15604215</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lee DI, Zhu G, Sasaki T, Cho GS, Hamdani N, Holewinski R, Jo SH, Danner T, Zhang M, Rainer PP, et al.  (2015) Phosphodiesterase 9A controls nitric-oxide-independent cGMP and hypertrophic heart disease. Nature
519: 472–476. 10.1038/nature14332</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature14332</ArticleId>
            <ArticleId IdType="pmc">PMC4376609</ArticleId>
            <ArticleId IdType="pubmed">25799991</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lips DJ, Bueno OF, Wilkins BJ, Purcell NH, Kaiser RA, Lorenz JN, Voisin L, Saba-El-Leil MK, Meloche S, Pouysségur J, et al.  (2004) MEK1-ERK2 signaling pathway protects myocardium from ischemic injury in vivo. Circulation
109: 1938–1941. 10.1161/01.CIR.0000127126.73759.23</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/01.CIR.0000127126.73759.23</ArticleId>
            <ArticleId IdType="pubmed">15096454</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu GY, Sabatini DM (2020) mTOR at the nexus of nutrition, growth, ageing and disease. Nat Rev Mol Cell Biol
21: 183–203. 10.1038/s41580-019-0199-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41580-019-0199-y</ArticleId>
            <ArticleId IdType="pmc">PMC7102936</ArticleId>
            <ArticleId IdType="pubmed">31937935</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ma L, Chen Z, Erdjument-Bromage H, Tempst P, Pandolfi PP (2005) Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis. Cell
121: 179–193. 10.1016/j.cell.2005.02.031</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2005.02.031</ArticleId>
            <ArticleId IdType="pubmed">15851026</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Tee AR, Logsdon MN, Blenis J, Cantley LC (2002) Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol Cell
10: 151–162. 10.1016/s1097-2765(02)00568-3</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s1097-2765(02)00568-3</ArticleId>
            <ArticleId IdType="pubmed">12150915</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Manning BD, Toker A (2017) AKT/PKB signaling: Navigating the network. Cell
169: 381–405. 10.1016/j.cell.2017.04.001</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2017.04.001</ArticleId>
            <ArticleId IdType="pmc">PMC5546324</ArticleId>
            <ArticleId IdType="pubmed">28431241</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Menon S, Dibble CC, Talbott G, Hoxhaj G, Valvezan AJ, Takahashi H, Cantley LC, Manning BD (2014) Spatial control of the TSC complex integrates insulin and nutrient regulation of mTORC1 at the lysosome. Cell
156: 771–785. 10.1016/j.cell.2013.11.049</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2013.11.049</ArticleId>
            <ArticleId IdType="pmc">PMC4030681</ArticleId>
            <ArticleId IdType="pubmed">24529379</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mohan ML, Chatterjee A, Ganapathy S, Mukherjee S, Srikanthan S, Jolly GP, Anand RS, Prasad SVN (2017) Noncanonical regulation of insulin-mediated ERK activation by phosphoinositide 3-kinase γ. Mol Biol Cell
28: 3112–3122. 10.1091/mbc.E16-12-0864</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1091/mbc.E16-12-0864</ArticleId>
            <ArticleId IdType="pmc">PMC5662266</ArticleId>
            <ArticleId IdType="pubmed">28877982</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mungai PT, Waypa GB, Jairaman A, Prakriya M, Dokic D, Ball MK, Schumacker PT (2011) Hypoxia triggers AMPK activation through reactive oxygen species-mediated activation of calcium release-activated calcium channels. Mol Cell Biol
31: 3531–3545. 10.1128/MCB.05124-11</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/MCB.05124-11</ArticleId>
            <ArticleId IdType="pmc">PMC3165558</ArticleId>
            <ArticleId IdType="pubmed">21670147</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nakamura T, Ranek MJ, Lee DI, Shalkey Hahn V, Kim C, Eaton P, Kass DA (2015) Prevention of PKG1α oxidation augments cardioprotection in the stressed heart. J Clin Invest
125: 2468–2472. 10.1172/JCI80275</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI80275</ArticleId>
            <ArticleId IdType="pmc">PMC4497760</ArticleId>
            <ArticleId IdType="pubmed">25938783</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oeing CU, Jun S, Mishra S, Dunkerly-Eyring B, Chen A, Grajeda MI, Tahir U, Gerszten RE, Paolocci N, Ranek MJ, et al.  (2021) MTORC1-Regulated metabolism controlled by TSC2 limits cardiac reperfusion injury. Circ Res
128: 639–651. 10.1161/circresaha.120.317710</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/circresaha.120.317710</ArticleId>
            <ArticleId IdType="pmc">PMC8257748</ArticleId>
            <ArticleId IdType="pubmed">33401933</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oeing CU, Nakamura T, Pan S, Mishra S, Dunkerly-Eyring BL, Kokkonen-Simon KM, Lin BL, Chen A, Zhu G, Bedja D, et al.  (2020) PKG1α cysteine-42 redox state controls mTORC1 activation in pathological cardiac hypertrophy. Circ Res
127: 522–533. 10.1161/CIRCRESAHA.119.315714</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1161/CIRCRESAHA.119.315714</ArticleId>
            <ArticleId IdType="pmc">PMC7416445</ArticleId>
            <ArticleId IdType="pubmed">32393148</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Potter CJ, Pedraza LG, Xu T (2002) Akt regulates growth by directly phosphorylating Tsc2. Nat Cell Biol
4: 658–665. 10.1038/ncb840</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ncb840</ArticleId>
            <ArticleId IdType="pubmed">12172554</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ranek MJ, Kokkonen-Simon KM, Chen A, Dunkerly-Eyring BL, Vera MP, Oeing CU, Patel CH, Nakamura T, Zhu G, Bedja D, et al.  (2019) PKG1-modified TSC2 regulates mTORC1 activity to counter adverse cardiac stress. Nature
566: 264–269. 10.1038/s41586-019-0895-y</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-019-0895-y</ArticleId>
            <ArticleId IdType="pmc">PMC6426636</ArticleId>
            <ArticleId IdType="pubmed">30700906</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA (2005) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med
11: 214–222. 10.1038/nm1175</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm1175</ArticleId>
            <ArticleId IdType="pubmed">15665834</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Takimoto E, Koitabashi N, Hsu S, Ketner EA, Zhang M, Nagayama T, Bedja D, Gabrielson KL, Blanton R, Siderovski DP, et al.  (2009) Regulator of G protein signaling 2 mediates cardiac compensation to pressure overload and antihypertrophic effects of PDE5 inhibition in mice. J Clin Invest
119: 408–420. 10.1172/JCI35620</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1172/JCI35620</ArticleId>
            <ArticleId IdType="pmc">PMC2631292</ArticleId>
            <ArticleId IdType="pubmed">19127022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M, Fumagalli S, Allegrini PR, Kozma SC, Auwerx J, et al.  (2004) Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature
431: 200–205. 10.1038/nature02866</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature02866</ArticleId>
            <ArticleId IdType="pubmed">15306821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Valvezan AJ, Manning BD (2019) Molecular logic of mTORC1 signalling as a metabolic rheostat. Nat Metab
1: 321–333. 10.1038/s42255-019-0038-7</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s42255-019-0038-7</ArticleId>
            <ArticleId IdType="pubmed">32694720</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Viscarra J, Kim SJ, Sul HS (2015) Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol
16: 678–689. 10.1038/nrm4074</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrm4074</ArticleId>
            <ArticleId IdType="pmc">PMC4884795</ArticleId>
            <ArticleId IdType="pubmed">26490400</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang H, Yu Z, Chen X, Li J, Li N, Cheng J, Gao N, Yuan HX, Ye D, Guan KL, et al.  (2021) Structural insights into TSC complex assembly and GAP activity on Rheb. Nat Commun
12: 339. 10.1038/s41467-020-20522-4</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-020-20522-4</ArticleId>
            <ArticleId IdType="pmc">PMC7804450</ArticleId>
            <ArticleId IdType="pubmed">33436626</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yu Q, Gao F, Ma XL (2011) Insulin says NO to cardiovascular disease. Cardiovasc Res
89: 516–524. 10.1093/cvr/cvq349</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cvr/cvq349</ArticleId>
            <ArticleId IdType="pubmed">21051417</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang HH, Huang J, Düvel K, Boback B, Wu S, Squillace RM, Wu CL, Manning BD (2009) Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway. PLoS One
4: e6189. 10.1371/journal.pone.0006189</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0006189</ArticleId>
            <ArticleId IdType="pmc">PMC2703782</ArticleId>
            <ArticleId IdType="pubmed">19593385</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
